The integration of artificial intelligence (AI) into clinical trials is poised to revolutionize health equity by addressing longstanding disparities in medical research. AI can enhance patient diversity and ensure that trials reflect real-world populations, leading to more inclusive and effective treatments. In this article for Clinical Leader, Shaheen Lakhan, Chief Medical and Strategy Officer of Click Therapeutics, shares AI's role in decentralized clinical trials (DCTs) and how embracing AI responsibly in clinical research can pave the way for a more equitable healthcare future. Read the full article in Clinical Leader.